Pharmacology and Toxicology Testing: IC50 for Tumor Cell Lines
Half maximal inhibitory concentration, or IC50, is a measurement representing the halfway point in which a compound of interest produces complete inhibition of a biological or biochemical function. This information is derived based on pharmacological data in reference to a dose-response curve. As the dosage of an inhibitory compound is increased, the biological function it affects decreases, and the point at which the concentration of the inhibitor has suppressed 50% of the biological activity is referred to as the IC50. IC50 is most often used as a measurement of antagonist, or inhibitory drug potency, as well as a quantification of the toxicological effects of inhibitory compounds.
During the development of Investigational New Drug (IND) applications, in vitro and in vivo toxicology testing studies are important to determine the threshold of inhibition of biological functions and effects of the compound on metabolism. In an effort to evaluate new pharmaceutical drugs and therapeutic treatments, cancer cell lines are used as in vitro models to screen the candidate drugs. Altogen Labs maintains a large library of cell lines that can be used for in vitro IC50 studies (see Table 1 below for some selected examples) and has the capacity to utilize client-provided cell lines as well.
Download Altogen Labs’ IC-50 Research Service PowerPoint Presentation: [Download ]
Get Instant Quote for
Pharmacology & Toxicology Testing:
IC50 for Tumor Cell Lines
Table 1. Selected cancer cell lines available at Altogen Labs for in vitro IC50 testing:
Disease / Tumor Type: | Cell Line / ID |
Breast Adenocarcinoma | SKBR3 (HTB30), MDA-MB (HTB26), MCF7 (HTB22) |
Burkitt’s Lymphoma | Daudi (CCL-213), Raji (CCL-86), Ramos (CRL-1596) |
Colon Carcinoma | Caco2 (HTB37), LS174T (CL188), SW480 (CCL228) |
Lung Adenocarcinoma | NCI-H460 (HTB-177), NCI-H23 (CRL-5800) |
Leukemia | K-562 (CCL-243), CCRF-CEM (CCL-119) |
Lewis Lung Carcinoma | Calu-3 (HTB-55), Calu-6 (HTB-56), A549 (CCL-185) |
Kidney | MDCK (CCL34), Cos7 (CRL1651), HEK293 (CRL1573) |
Melanoma | J774A.1 (TIB-67), SK-MEL-28 (HTB-72) |
Neuroblastoma | SK-N-SH (HTB-11), Neuro-2a (CCL-131) |
Osteosarcoma | MG-63 (CRL-1427), SK-OV-3 (HTB-77) |
Ovarian Adenocarcinoma | Beta-TC-6 (CRL-11506), CHO-K1 (CRL-9618) |
Pancreatic Carcinoma | Capan-1 (HTB-79), MIA PaCa-2 (CRL-1420) |
Prostate Carcinoma | LNCaP (CRL-1740), DU145 (HTB-81) |
Rhabdomyosarcoma | Detroit 551 (CCL-110) |
At Altogen Labs, we recognize that providing fast delivery of products and services is critical to expediting research. We are committed to meeting our clients’ timely needs while maintaining high quality and integrity. All of our services undergo rigorous QC procedures.
Download Altogen Labs In Vivo Toxicology Services PowerPoint Presentation: [PPT]
Once we know the details of your project, we can provide you an immediate price quote (contact us via e-mail at info@altogenlabs.com or call Altogen Labs at 512-433-6177). Please note that experimental details will help us to provide an accurate quote and timeline estimate.
Get Instant Quote for
Pharmacology & Toxicology Testing:
IC50 for Tumor Cell Lines
Complete list of cancer cell lines available at Altogen Labs for IC-50 study:
Get Instant Quote for
Pharmacology & Toxicology Testing:
IC50 for Tumor Cell Lines